M. Meyer

发表

Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer.

H Steininger, J. Hornung, G. Grabenbauer, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α‐fetoprotein status

H. Zentgraf, P. Galle, B. Kommerell, 1993 .

p27kip1 Expression in Rectal Cancer Correlates with Disease-Free Survival

K. Matzel, W. Hohenberger, K. Günther, 2000 .

D3 lymph node dissection in gastric cancer: Evaluation of postoperative mortality and complications

W. Hohenberger, T. Horbach, K. Günther, 2010, Surgery Today.

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

J. Dunst, C. Rödel, G. Grabenbauer, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Drug Interaction Study of Suramin and Warfarin in Patients With Prostate Cancer

W. Slichenmyer, M. Meyer, M. Meyer, 2001, American journal of clinical oncology.

Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.

T. Lehnert, H. Zentgraf, P. Galle, 2006, International journal of oncology.

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

E. Small, W. Slichenmyer, M. Meyer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.

O. Ganslandt, G. Grabenbauer, M. Meyer, 2009, International journal of radiation oncology, biology, physics.

The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status.

H. Zentgraf, P. Galle, B. Kommerell, 1993, Hepatology.

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

F. Meyers, E. Small, W. Slichenmyer, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proliferative activity measured by flow cytometry and Ki‐67 of nodal negative breast cancer as a prognostic parameter for local recurrences and distant metastases ‐first results

R. Sauer, M. Meyer, R. Fietkau, 1994 .

Sphincter preservation with chemoradiation in anal canal carcinoma

K. Matzel, W. Hohenberger, G. Grabenbauer, 1998, Diseases of the colon and rectum.

The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α‐fetoprotein status

H. Zentgraf, P. Galle, B. Kommerell, 1993, Hepatology.

p27(kip1) expression in rectal cancer correlates with disease-free survival.

K. Matzel, W. Hohenberger, K. Günther, 2000, The Journal of surgical research.

140Prognostic significance of proliferation associated antigens (PCNA, Ki-67) and p53-expression in inoperable head and neck cancer after accelerated split-course radiation

G. Grabenbauer, R. Sauer, H. Steininger, 1996 .

[Hypoxyradiotherapy: changes in the oxygen partial pressure distribution in the tumor and in the healthy tissue under acute respiratory hypoxia].

R. Sauer, M. Meyer, J. Jahns, 1996, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].